JOP20190239A1 - مركبات مثبطة لـ vmat2 وتركيبات منها - Google Patents
مركبات مثبطة لـ vmat2 وتركيبات منهاInfo
- Publication number
- JOP20190239A1 JOP20190239A1 JOP/2019/0239A JOP20190239A JOP20190239A1 JO P20190239 A1 JOP20190239 A1 JO P20190239A1 JO P20190239 A JOP20190239 A JO P20190239A JO P20190239 A1 JOP20190239 A1 JO P20190239A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- compositions
- inhibitor compounds
- vmat2 inhibitor
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US201862652837P | 2018-04-04 | 2018-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190239A1 true JOP20190239A1 (ar) | 2019-10-09 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0239A JOP20190239A1 (ar) | 2017-04-19 | 2017-06-16 | مركبات مثبطة لـ vmat2 وتركيبات منها |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (https=) |
| EP (1) | EP3612532B1 (https=) |
| JP (1) | JP7170662B2 (https=) |
| KR (1) | KR20190140968A (https=) |
| CN (1) | CN110770236B (https=) |
| AU (1) | AU2018254429A1 (https=) |
| BR (1) | BR112019021853A2 (https=) |
| CA (1) | CA3060251A1 (https=) |
| CL (1) | CL2019002919A1 (https=) |
| CO (1) | CO2019011604A2 (https=) |
| ES (1) | ES2971230T3 (https=) |
| JO (1) | JOP20190239A1 (https=) |
| MA (1) | MA50145A (https=) |
| MX (1) | MX2019012336A (https=) |
| PE (1) | PE20191784A1 (https=) |
| TW (1) | TW201841913A (https=) |
| WO (1) | WO2018195121A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3051830A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| AU2019287524A1 (en) * | 2018-06-14 | 2020-12-24 | Neurocrine Biosciences, Inc. | VMAT2 inhibitor compounds, compositions, and methods relating thereto |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| WO2020086765A1 (en) * | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| PE20221038A1 (es) | 2019-09-30 | 2022-06-17 | Incyte Corp | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| AU2022241988A1 (en) | 2021-03-22 | 2023-10-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
| JP2008509925A (ja) * | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9012471B2 (en) * | 2008-04-11 | 2015-04-21 | The Trustees Of Columbia University In The City Of New York | Glucose metabolism modulating compounds |
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US8772301B2 (en) * | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| EP2835372B1 (en) | 2012-09-19 | 2016-05-04 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Thiophene [2, 3-d]pyrimidine derivative, and preparation method and use thereof |
| CN106061506A (zh) | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| US9714246B2 (en) | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en not_active Ceased
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 ES ES18722357T patent/ES2971230T3/es active Active
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko not_active Withdrawn
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019012336A (es) | 2020-07-14 |
| JP7170662B2 (ja) | 2022-11-14 |
| EP3612532A1 (en) | 2020-02-26 |
| WO2018195121A1 (en) | 2018-10-25 |
| US11040970B2 (en) | 2021-06-22 |
| EP3612532B1 (en) | 2023-12-13 |
| CL2019002919A1 (es) | 2020-01-17 |
| ES2971230T3 (es) | 2024-06-04 |
| EP3612532C0 (en) | 2023-12-13 |
| TW201841913A (zh) | 2018-12-01 |
| JP2020517607A (ja) | 2020-06-18 |
| KR20190140968A (ko) | 2019-12-20 |
| CN110770236B (zh) | 2023-03-24 |
| AU2018254429A1 (en) | 2019-11-07 |
| PE20191784A1 (es) | 2019-12-24 |
| CO2019011604A2 (es) | 2019-10-31 |
| BR112019021853A2 (pt) | 2020-05-26 |
| CA3060251A1 (en) | 2018-10-25 |
| MA50145A (fr) | 2020-07-29 |
| US20200131173A1 (en) | 2020-04-30 |
| CN110770236A (zh) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190239A1 (ar) | مركبات مثبطة لـ vmat2 وتركيبات منها | |
| MX375718B (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| MX2017010230A (es) | Derivados de mono- y poliazanaftaleno sustituidos y su uso. | |
| MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
| HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2015008971A (es) | Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor. | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| NZ532494A (en) | Dibenzylamine compound and medicinal use thereof | |
| TW201613875A (en) | EGFR inhibitors, their preparation and their use thereof | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| UA117151C2 (uk) | N-ациліміногетероциклічні сполуки | |
| MX2020010181A (es) | Compuestos de piperidina como inhibidores covalentes de menina. | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| EA200601178A1 (ru) | Морфолинилсодержащие бензимидазолы в качестве ингибиторов репликации респираторно-синцитиального вируса | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина | |
| MX2016003630A (es) | Compuestos heterociclicos de n-acilimino. | |
| SA522441473B1 (ar) | Cdk7 مركبات مفيدة لتثبيط |